12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALS-2158: Development discontinued

Vertex and partner Alios discontinued development of ALS-2158 after data from a double-blind, placebo-controlled, Australian and New Zealand Phase I trial in patients with HCV genotype 1 infection showed that the compound...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >